Statistik Asas
| LEI | 5493006HSPECSOT1UH87 |
| CIK | 1723980 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to China SXT Pharmaceuticals, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| July 31, 2025 |
Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Feng Zhou, certify that: 1. I have reviewed this annual report on Form 20-F of China SXT Pharmaceuticals, Inc. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statem |
|
| July 31, 2025 |
Certifications Pursuant to 18 U.S.C. Section 1350 Exhibit 13.1 Certifications Pursuant to 18 U.S.C. Section 1350 Pursuant to U.S.C. Section 1350 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), each of the undersigned officers of China SXT Pharmaceuticals, Inc. (the “Company”), does hereby certify, to such officer’s knowledge, that: The Annual Report on Form 20-F for the year |
|
| July 31, 2025 |
Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Xiaodong Pan, certify that: 1. I have reviewed this annual report on Form 20-F of China SXT Pharmaceuticals, Inc. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue sta |
|
| July 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1 |
|
| July 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Commission File No. 001-38773 CHINA SXT PHARMACEUTICALS, INC. (Translation of registrant’s name into English) 178 Taidong Rd North, Taizhou Jiangsu, China (Address of principal execut |
|
| July 29, 2025 |
Exhibit 3.1 BVI COMPANY NUMBER: 1949664 TERRITORY OF THE BRITISH VIRGIN ISLANDS THE BVI BUSINESS COMPANIES ACT (AS REVISED) MEMORANDUM AND ARTICLES OF ASSOCIATION OF China SXT Pharmaceuticals, Inc. Incorporated on the 4th day of July, 2017 Amended and restated on the 17th day of May, 2022 Amended and restated on the 29th day of September, 2023 Amended and restated on this 28th day of July, 2025 IN |
|
| July 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 CHINA SXT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) 178 Taidong Rd North, Taizhou Jiangsu, China (Address of Principal Executive Office) Indicate by |
|
| July 15, 2025 |
Exhibit 99.2 CHINA SXT PHARMACEUTICALS, INC. 178 Taidong Road North, Taizhou, Jiangsu, People’s Republic of China NOTICE OF 2025 SPECIAL MEETING OF SHAREHOLDERS To Be Held at 9 A.M. EST on July 28, 2025 (Record Date — July 9, 2025) THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned hereby appoints Feng Zhou, as proxy of the undersigned, with full power to appoint his subst |
|
| July 15, 2025 |
Exhibit 99.1 CHINA SXT PHARMACEUTICALS, INC. (incorporated in the British Virgin Islands with limited liability) (NASDAQ: SXTC) NOTICE OF 2025 SPECIAL MEETING OF SHAREHOLDERS To be held on July 28, 2025, at 9 a.m., EST To the Shareholders of China SXT Pharmaceuticals, Inc.: This proxy statement is furnished in connection with the solicitation of proxies by the Board of Directors (the “Board”) of C |
|
| June 16, 2025 |
ORDINARY SHARE PURCHASE WARRANT CHINA SXT PHARMACEUTICALS, INC. Exhibit 10.2 ORDINARY SHARE PURCHASE WARRANT CHINA SXT PHARMACEUTICALS, INC. Warrant Shares: [insert number] Issue Date: May 16, 2025 THIS ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [ investor’s Name] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on |
|
| June 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number: 001-38773 CHINA SXT PHARMACEUTICALS, INC. (Translation of registrant’s name into English) 178 Taidong Rd North, Taizhou Jiangsu, China (Address of principal ex |
|
| June 16, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 16, 2025, between CHINA SXT PHARMACEUTICALS, INC., a BVI business company incorporated and registered in the British Virgin Islands with limited liability (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purc |
|
| May 19, 2025 |
Filed pursuant to Rule 424(b)(5) Registration Statement Number 333-282776 PROSPECTUS SUPPLEMENT (To Prospectus dated October 22, 2024) China SXT Pharmaceuticals, Inc. |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-38773 CHINA SXT PHARMACEUTICALS, INC. (Translation of registrant’s name into English) 178 Taidong Rd North, Taizhou Jiangsu, China (Address of principal exe |
|
| May 13, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 5, 2025, between China SXT Pharmaceuticals, Inc., a British Virgin Islands company (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms |
|
| May 7, 2025 |
China SXT Pharmaceuticals, Inc. 200,000 Ordinary Shares Filed pursuant to Rule 424(b)(5) Registration Statement Number 333-282776 PROSPECTUS SUPPLEMENT (To Prospectus dated October 22, 2024) China SXT Pharmaceuticals, Inc. |
|
| March 28, 2025 |
CHINA SXT PHARMACEUTICALS, INC. 2025 EQUITY INCENTIVE PLAN Exhibit 4.2 CHINA SXT PHARMACEUTICALS, INC. 2025 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are: ● to attract and retain the best available personnel for positions of substantial responsibility, ● to provide additional incentive to Employees, Directors and Consultants, and ● to promote the success of the Company’s business. The Plan permits the grant of Incentive Stoc |
|
| March 28, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) China SXT Pharmaceuticals, Inc. |
|
| March 28, 2025 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.1 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of our results of operations and financial condition should be read together with our unaudited condensed consolidated financial statements and the notes thereto and other financial information, which are included elsewhere in this Current Report on Form 6-K. Our |
|
| March 28, 2025 |
As filed with the Securities and Exchange Commission on March 28, 2025 As filed with the Securities and Exchange Commission on March 28, 2025 Registration No. |
|
| March 28, 2025 |
Exhibit 99.2 CHINA SXT PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED SEPTEMBER 30, 2024 AND 2023 (UNAUDITED) CHINA SXT PHARMACEUTICALS, INC. INDEX TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Condensed Consolidated Financial Statements Condensed Consolidated Balance Sheets as of September 30, 2024 (Unaudited) and March 31, 2024 F-2 Condensed Consolida |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number: 001-38773 CHINA SXT PHARMACEUTICALS, INC. (Translation of registrant’s name into English) 178 Taidong Rd North, Taizhou Jiangsu, China (Address of principal e |
|
| March 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number: 001-38773 CHINA SXT PHARMACEUTICALS, INC. (Translation of registrant’s name into English) 178 Taidong Rd North, Taizhou Jiangsu, China (Address of principal e |
|
| March 19, 2025 |
Exhibit 99.1 WARRANT EXCHANGE AGREEMENT This Warrant Exchange Agreement (this “Agreement”) between China SXT Pharmaceuticals, Inc. (the “Company”) and the undersigned hereto (each, a “Holder”, collectively, the “Holders”; together with the Company, the “Parties” and, each, a “Party”) is dated March 13, 2025. Capitalized terms that are not defined herein shall have the meanings as set forth in the |
|
| January 27, 2025 |
Exhibit 99.4 LOAN AGREEMENT This LOAN AGREEMENT (the “Agreement”) is made and entered into as of January 15, 2025 (the “Effective Date”), by and between: 1. Lenders: Lenders identified on the signature pages hereto (each, including its successors and assigns, each a “Lender” and collectively, the “Lenders”). 2. Borrower: CHINA SXT PHARMACEUTICALS, INC., a company organized in the British Virgin Is |
|
| January 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File Number: 001-38773 CHINA SXT PHARMACEUTICALS, INC. (Translation of registrant’s name into English) 178 Taidong Rd North, Taizhou Jiangsu, China (Address of principal |
|
| January 27, 2025 |
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK SIGNATURE PAGES FOLLOW] Exhibit 99.3 January 21, 2025 CHINA SXT PHARMACEUTICALS, INC. 178 Taidong Rd North, Taizhou Jiangsu, China Attention: Feng Zhou, CEO Re: Surrender of Debt To Whom It May Concern, 1. Reference to Loan and Assignment I refer to a certain Loan Agreement dated January 15, 2025 (the “Loan Agreement”) by and between the me (“Lender”) and China SXT Pharmaceuticals, Inc. (the “Company” or “Borrower”), und |
|
| January 27, 2025 |
ORDINARY SHARE PURCHASE WARRANT CHINA SXT PHARMACEUTICALS, INC. Exhibit 99.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| January 27, 2025 |
Exhibit 99.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 21, 2025, between China SXT Pharmaceuticals, Inc., a British Virgin Islands company (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the |
|
| January 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File Number: 001-38773 CHINA SXT PHARMACEUTICALS, INC. (Translation of registrant’s name into English) 178 Taidong Rd North, Taizhou Jiangsu, China (Address of principal |
|
| January 23, 2025 |
Exhibit 99.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”), is entered into as of [ ] (the “Effective Date”), by and between China SXT Pharmaceuticals, Inc., incorporated under the laws of the British Virgin Islands (the “Company”), and Simon Lim Sze Beng, an individual (the “Co-Chief Executive Officer (Co-CEO)”). Except with respect to the direct employment of the Co-CEO by the |
|
| January 23, 2025 |
CHINA SXT PHARMACEUTICALS, INC. 178 Taidong Rd North, Taizhou Jiangsu, China Exhibit 99.2 CHINA SXT PHARMACEUTICALS, INC. 178 Taidong Rd North, Taizhou Jiangsu, China [ ], 2025 Re: Director Offer Letter Dear [ ]: CHINA SXT PHARMACEUTICALS, INC., a British Virgin Islands exempt company (the “Company”), is pleased to offer you a position as a member of its Board of Directors (the “Board”). We believe your background and experience will be a significant asset to the Company a |
|
| November 1, 2024 |
China SXT Pharmaceuticals, Inc. China SXT Pharmaceuticals, Inc. November 1, 2024 Via Edgar United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549 Attn: Chris Edwards Re: China SXT Pharmaceuticals, Inc. Registration Statement on Form F-3 Filed on October 22, 2024 File No. 333-282776 Ladies and Gentlemen: In accordance with Rule 461 of the Ge |
|
| October 22, 2024 |
Exhibit 4.4 CHINA SXT PHARMACEUTICALS, INC. (the “Issuer”) AND [TRUSTEE] (the “Trustee”) INDENTURE Dated as of [●], 20[●] Senior Debt Securities TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities |
|
| October 22, 2024 |
Exhibit 107 Calculation of Filing Fee Tables F-3 (Form Type) China SXT Pharmaceuticals, Inc. |
|
| October 22, 2024 |
Exhibit 4.5 CHINA SXT PHARMACEUTICALS, INC. Issuer AND [TRUSTEE] Trustee INDENTURE Dated as of [●], 20[●] Subordinated Debt Securities TABLE OF CONTENTS ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms. 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities. 4 Section 2.02 Form of Securities and Trustee’ |
|
| October 22, 2024 |
As filed with the Securities and Exchange Commission on October 22, 2024 As filed with the Securities and Exchange Commission on October 22, 2024 Registration No. |
|
| October 15, 2024 |
Exhibit 16.1 October 12, 2024 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Dear Sir or Madam: We have been furnished with a copy of the Form 6-K for the event that occurred on October 9, 2024, to be filed by our former client, China SXT Pharmaceuticals, Inc. We agree with the statements concerning our firm contained in such Form 6-K. We have no position to agree or |
|
| October 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number: 001-38773 CHINA SXT PHARMACEUTICALS, INC. (Translation of registrant’s name into English) 178 Taidong Rd North, Taizhou Jiangsu, China (Address of principal |
|
| August 15, 2024 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Amendment no. 3) (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2. Under the Securities Exchange Act of 1934 China SXT Pharmaceuticals Inc (Name of Issuer) COMMON STOCK, PAR VALUE $0.08PER SHARE (Title of Class of Securiti |
|
| August 13, 2024 |
CODE OF BUSINESS CONDUCT AND ETHICS OF CHINA SXT PHARMACEUTICALS, INC. Exhibit 11 CODE OF BUSINESS CONDUCT AND ETHICS OF CHINA SXT PHARMACEUTICALS, INC. INTRODUCTION Purpose This Code of Business Conduct and Ethics (this “Code”) contains general guidelines for the conduct of business of China SXT Pharmaceuticals, Inc., a British Virgin Islands business company limited by shares (the “Company”), consistent with the highest standards of business ethics. To the extent w |
|
| August 13, 2024 |
Exhibit 15.1 August 13, 2024 To: China SXT Pharmaceuticals, Inc. 178 Taidong Rd North, Taizhou Jiangsu, China Dear Sir/Madam, We hereby consent to the references to our firm’s name under the headings “Item 3. Key Information—D. Risk Factors—Risk Factors Relating to Doing Business in China”, “Item 4. Information on the Company—B. Business Overview— Permissions or Approval Required from the PRC Auth |
|
| August 13, 2024 |
Exhibit 97 CHINA SXT PHARMACEUTICALS, INC. the “Company” COMPENSATION RECOVERY POLICY Effective December 1, 2023 In accordance with Section 10D of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), Exchange Act Rule 10D-1, and the listing standards of The Nasdaq Stock Market (the “Exchange”), the Company’s Board of Directors (the “Board”) has adopted this Compensation Recovery P |
|
| August 13, 2024 |
Exhibit 1.5 BVI COMPANY NUMBER: 1949664 TERRITORY OF THE BRITISH VIRGIN ISLANDS THE BVI BUSINESS COMPANIES ACT, 2004 MEMORANDUM AND ARTICLES OF ASSOCIATION OF China SXT Pharmaceuticals, Inc. Incorporated on the 4th day of July, 2017 Amended and restated on the 17th day of May, 2022 Amended and restated on the 29th day of September, 2023 INCORPORATED IN THE BRITISH VIRGIN ISLANDS - 1 - China SXT Ph |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1 |
|
| August 13, 2024 |
Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Xiaodong Pan, certify that: 1. I have reviewed this annual report on Form 20-F of China SXT Pharmaceuticals, Inc. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue sta |
|
| August 13, 2024 |
Certifications Pursuant to 18 U.S.C. Section 1350 Exhibit 13.1 Certifications Pursuant to 18 U.S.C. Section 1350 Pursuant to U.S.C. Section 1350 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), each of the undersigned officers of China SXT Pharmaceuticals, Inc. (the “Company”), does hereby certify, to such officer’s knowledge, that: The Annual Report on Form 20-F for the year |
|
| August 13, 2024 |
Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Feng Zhou, certify that: 1. I have reviewed this annual report on Form 20-F of China SXT Pharmaceuticals, Inc. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statem |
|
| July 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☒ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| May 31, 2024 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Amendment no. 2) (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2. Under the Securities Exchange Act of 1934 China SXT Pharmaceuticals Inc (Name of Issuer) COMMON STOCK, PAR VALUE $0.08PER SHARE (Title of Class of Securiti |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-38773 CHINA SXT PHARMACEUTICALS, INC. (Translation of registrant’s name into English) 178 Taidong Rd North, Taizhou Jiangsu, China (Address of principal exe |
|
| May 14, 2024 |
Exhibit 10.1 Securities Purchase Agreement This Securities Purchase Agreement (this “Agreement”), dated as of May 9, 2024, is entered into by and between China SXT Pharmaceuticals, Inc., a British Virgin Islands corporation (“Company”), and Streeterville Capital, LLC, a Utah limited liability company, its successors and/or assigns (“Investor”). A. Company and Investor are executing and delivering |
|
| May 14, 2024 |
Exhibit 10.5 CONVERTIBLE PROMISSORY NOTE March 27, 2024 U.S. $531,666.67 FOR VALUE RECEIVED, China SXT Pharmaceuticals, Inc., a British Virgin Islands corporation (“Borrower”), promises to pay to Streeterville Capital, LLC, a Utah limited liability company, or its successors or assigns (“Lender”), $531,666.67 and any interest, fees, charges, and late fees accrued hereunder on the date that is twel |
|
| May 14, 2024 |
Exhibit 10.3 securities purchase agreement This Securities Purchase Agreement (this “Agreement”), dated as of December 13, 2023, is entered into by and between China SXT Pharmaceuticals, Inc., a British Virgin Islands corporation (“Company”), and Streeterville Capital, LLC, a Utah limited liability company, its successors and/or assigns (“Investor”). A. Company and Investor are executing and deliv |
|
| May 14, 2024 |
Exhibit 10.6 CONVERTIBLE PROMISSORY NOTE December 13, 2023 U.S. $531,666.67 FOR VALUE RECEIVED, China SXT Pharmaceuticals, Inc., a British Virgin Islands corporation (“Borrower”), promises to pay to Streeterville Capital, LLC, a Utah limited liability company, or its successors or assigns (“Lender”), $531,666.67 and any interest, fees, charges, and late fees accrued hereunder on the date that is t |
|
| May 14, 2024 |
Exhibit 10.4 CONVERTIBLE PROMISSORY NOTE May 9, 2024 U.S. $797,500.00 FOR VALUE RECEIVED, China SXT Pharmaceuticals, Inc., a British Virgin Islands corporation (“Borrower”), promises to pay to Streeterville Capital, LLC, a Utah limited liability company, or its successors or assigns (“Lender”), $797,500.00 and any interest, fees, charges, and late fees accrued hereunder on the date that is twelve |
|
| May 14, 2024 |
Exhibit 10.2 Securities Purchase Agreement This Securities Purchase Agreement (this “Agreement”), dated as of March 27, 2024, is entered into by and between China SXT Pharmaceuticals, Inc., a British Virgin Islands corporation (“Company”), and Streeterville Capital, LLC, a Utah limited liability company, its successors and/or assigns (“Investor”). A. Company and Investor are executing and deliveri |
|
| April 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-38773 CHINA SXT PHARMACEUTICALS, INC. (Translation of registrant’s name into English) 178 Taidong Rd North, Taizhou Jiangsu, China (Address of principal e |
|
| April 5, 2024 |
Exhibit 99.1 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of our results of operations and financial condition should be read together with our unaudited condensed consolidated financial statements and the notes thereto and other financial information, which are included elsewhere in this Form 6-K. Our unaudited financi |
|
| April 5, 2024 |
Exhibit 99.2 CHINA SXT PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED SEPTEMBER 30, 2023 AND 2022 (UNAUDITED) CHINA SXT PHARMACEUTICALS, INC. INDEX TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Condensed Consolidated Financial Statements Condensed Consolidated Balance Sheets as of September 30, 2023 (Unaudited) and March 31, 2023 F-2 Condensed Consolida |
|
| February 9, 2024 |
SC 13G/A 1 tm245754d1sc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Amendment no. 1) (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2. Under the Securities Exchange Act of 1934 China SXT Pharmaceuticals Inc (Name of Issuer) COMMON STOCK, PAR VALUE $ |
|
| February 9, 2024 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2. Under the Securities Exchange Act of 1934 China SXT Pharmaceuticals Inc (Name of Issuer) COMMON STOCK, PAR VALUE $0.08PER SHARE (Title of Class of Securities) G2161P140 (CUS |
|
| January 11, 2024 |
Exhibit 107 Calculation of Filing Fee Tables S-8 (Form Type) CHINA SXT PHARMACEUTICALS, INC (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Ordinary Shares 457(c) and 457(h) 185,316 2. |
|
| January 11, 2024 |
CHINA SXT PHARMARCEUTICALS, INC. 2024 EQUITY INCENTIVE PLAN Exhibit 4.2 CHINA SXT PHARMARCEUTICALS, INC. 2024 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are: ● to attract and retain the best available personnel for positions of substantial responsibility, ● to provide additional incentive to Employees, Directors and Consultants, and ● to promote the success of the Company’s business. The Plan permits the grant of Incentive Sto |
|
| January 11, 2024 |
As filed with the Securities and Exchange Commission on January 11, 2024 As filed with the Securities and Exchange Commission on January 11, 2024 Registration No. |
|
| July 31, 2023 |
Exhibit 2.2 Description of Rights of Each Class of Securities Registered under Section 12 of the Securities Exchange Act of 1934, as Amended (the “Exchange Act”) Ordinary shares, par value $0.08 each (“Ordinary Shares”), of China SXT Pharmaceuticals, Inc. (“we,” “our,” “our company,” or “us”) are listed and traded on the Nasdaq Capital Market, and in connection with this listing (but not for tradi |
|
| July 31, 2023 |
Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Feng Zhou, certify that: 1. I have reviewed this annual report on Form 20-F of China SXT Pharmaceuticals, Inc. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statem |
|
| July 31, 2023 |
Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Xiaodong Pan, certify that: 1. I have reviewed this annual report on Form 20-F of China SXT Pharmaceuticals, Inc. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue sta |
|
| July 31, 2023 |
Certifications Pursuant to 18 U.S.C. Section 1350 Exhibit 13.1 Certifications Pursuant to 18 U.S.C. Section 1350 Pursuant to U.S.C. Section 1350 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), each of the undersigned officers of China SXT Pharmaceuticals, Inc. (the “Company”), does hereby certify, to such officer’s knowledge, that: The Annual Report on Form 20-F for the year |
|
| July 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1 |
|
| May 19, 2023 |
Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Xiaodong Pan, certify that: 1. I have reviewed this annual report on Form 20-F, as amended, of China SXT Pharmaceuticals, Inc. (the “Company”); 2. Based on my knowledge, this report does not contain a |
|
| May 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO.1 TO FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES |
|
| May 19, 2023 |
Certifications Pursuant to 18 U.S.C. Section 1350 Exhibit 13.1 Certifications Pursuant to 18 U.S.C. Section 1350 Pursuant to U.S.C. Section 1350 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), each of the undersigned officers of China SXT Pharmaceuticals, Inc. (the “Company”), does hereby certify, to such officer’s knowledge, that: The Annual Report on Form 20-F, as amended, |
|
| May 19, 2023 |
Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Feng Zhou, certify that: 1. I have reviewed this annual report on Form 20-F, as amended, of China SXT Pharmaceuticals, Inc. (the “Company”); 2. Based on my knowledge, this report does not contain any |
|
| April 13, 2023 |
China SXT Pharmaceuticals, Inc. 178 Taidong Rd North, Taizhou Jiangsu, China China SXT Pharmaceuticals, Inc. 178 Taidong Rd North, Taizhou Jiangsu, China April 13, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549 Attn: Joe McCann Lauren Sprague Hamill Tara Harkins Lynn Dicker Re: China SXT Pharmaceuticals, Inc. Form 20-F for the Fiscal Year Ended March 31, 2022 Filed July |
|
| March 29, 2023 |
SXTC / China SXT Pharmaceuticals Inc / Streeterville Capital LLC - NONE Passive Investment SC 13G 1 doc1.htm NONE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* China SXT Pharmaceuticals, Inc. (Name of Issuer) Common stock, $0.08 par value (Title of Class of Securities) G2161P132 (CUSIP Number) March 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| March 29, 2023 |
SXTC / China SXT Pharmaceuticals Inc / Streeterville Capital LLC - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* China SXT Pharmaceuticals, Inc. (Name of Issuer) Common stock, $0.08 par value (Title of Class of Securities) G2161P132 (CUSIP Number) March 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design |
|
| March 27, 2023 |
Filed pursuant to Rule 424(b)(7) Registration No. 333-252664 Prospectus Supplement (To Prospectus dated February 2, 2021, as amended) $1,374,712 of ordinary shares issuable upon conversion of an unsecured convertible promissory note, offered by the Selling Shareholder of China SXT Pharmaceuticals, Inc. This prospectus relates to the offer and sale of up to $1,374,712 of ordinary shares, par value |
|
| March 23, 2023 |
Form of Securities Purchase Agreement Exhibit 10.1 Securities Purchase Agreement This Securities Purchase Agreement (this “Agreement”), dated as of March 7, 2023, is entered into by and between China SXT Pharmaceuticals, Inc., a British Virgin Islands corporation (“Company”), and Streeterville Capital, LLC, a Utah limited liability company, its successors and/or assigns (“Investor”). A. Company and Investor are executing and deliverin |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-38773 CHINA SXT PHARMACEUTICALS, INC. (Translation of registrant’s name into English) 178 Taidong Rd North, Taizhou Jiangsu, China (Address of principal e |
|
| March 23, 2023 |
Form of Convertible Promissory Note Exhibit 10.2 CONVERTIBLE PROMISSORY NOTE March 7, 2023 U.S. $2,126,666.67 FOR VALUE RECEIVED, China SXT Pharmaceuticals, Inc., a British Virgin Islands corporation (“Borrower”), promises to pay to Streeterville Capital, LLC, a Utah limited liability company, or its successors or assigns (“Lender”), $2,126,666.67 and any interest, fees, charges, and late fees accrued hereunder on the date that is t |
|
| February 28, 2023 |
Exhibit 4.1 VOTING RIGHTS PROXY AGREEMENT This Voting Rights Proxy Agreement (this “Agreement”) is entered into as of February 22, 2023 (“Effective Date”), by and between Rising Sun Capital Pty., Ltd., a limited liability company organized under the laws of Australia, (the “Shareholder”) and Feng Zhou Management Limited (“Zhou”). The Shareholder and Zhou are each referred to in this Agreement as a |
|
| February 28, 2023 |
Form of SPA, dated February 22, 2023, by and between the Company and Rising Sun Capital Ltd. Exhibit 10.1 SECURITIES PURCHASE AGREEMENT 证券购买协议 This SECURITIES PURCHASE AGREEMENT (the “Agreement”) is dated as of February 22, 2023 by and among China SXT Pharmaceuticals, Inc., a British Virgin Islands company, (the “Company”), and the entity which affixed its signature on the signature page of this Agreement (the “Purchaser”). 本证券购买协议(“本协议”或“协议”)于二零二三年二月二十二日，由江苏苏轩堂药业有限公司，一家英属维京群岛公司（“公司”），和在此 |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 Commission File Number: 001-38773 CHINA SXT PHARMACEUTICALS, INC. (Translation of registrant’s name into English) 178 Taidong Rd North, Taizhou Jiangsu, China (Address of principa |
|
| February 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 Commission File Number: 333-231839 CHINA SXT PHARMACEUTICALS, INC. (Translation of registrant’s name into English) 178 Taidong Rd North, Taizhou Jiangsu, China (Address of princip |
|
| February 24, 2023 |
Exhibit 99.2 CHINA SXT PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED SEPTEMBER 30, 2022 AND 2021 (UNAUDITED) CHINA SXT PHARMACEUTICALS, INC. INDEX TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Condensed Consolidated Financial Statements Condensed Consolidated Balance Sheets as of September 30, 2022 (Unaudited) and March 31, 2022 F-2 Condensed Consolida |
|
| February 24, 2023 |
Exhibit 99.1 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of our results of operations and financial condition should be read together with our unaudited condensed consolidated financial statements and the notes thereto and other financial information, which are included elsewhere in this Form 6-K. Our unaudited financi |
|
| February 13, 2023 |
SXTC / China SXT Pharmaceuticals Inc / Lind Global Fund II LP - AMENDMENT NO. 1 Passive Investment SC 13G/A 1 sc13ga.htm AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* China SXT Pharmaceuticals, Inc. (Name of Issuer) Ordinary Shares, $0.004 par value per share (Title of Class of Securities) G2161P132 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Stat |
|
| February 13, 2023 |
EX-99.1 2 exhibit99-1.htm JOINT FILING APPLICATION BY AND AMONG THE REPORTING PERSONS Exhibit 99.1 JOINT FILING APPLICATION The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Ordinary Shares, $0.004 par value per share, of China SXT Pharmaceuticals, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an |
|
| January 30, 2023 |
Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13D referred to below) on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the ordinary shares, par value of US$0. |
|
| January 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Amendment No. 1 Under the Securities Exchange Act of 1934 China SXT Pharmaceuticals, Inc. (Name of Company) Ordinary Shares, $0.08 Par Value Per Share (Title of Class of Securities) G2161P132 (CUSIP Number) Feng Zhou 178 Taidong Rd North, Taizhou Jiangsu, China +86-523-86298290 (Name, Address and Telephone Number |
|
| December 23, 2022 |
Form of Convertible Promissory Note Exhibit 10.2 CONVERTIBLE PROMISSORY NOTE , 2022 U.S. $1,595,000.00 FOR VALUE RECEIVED, China SXT Pharmaceuticals, Inc., a British Virgin Islands corporation (?Borrower?), promises to pay to Streeterville Capital, LLC, a Utah limited liability company, or its successors or assigns (?Lender?), $1,595,000.00 and any interest, fees, charges, and late fees accrued hereunder on the date that is twelve ( |
|
| December 23, 2022 |
Form of Securities Purchase Agreement exhibit 10.1 Securities Purchase Agreement This Securities Purchase Agreement (this ?Agreement?), dated as of December 19, 2022, is entered into by and between China SXT Pharmaceuticals, Inc., a British Virgin Islands corporation (?Company?), and Streeterville Capital, LLC, a Utah limited liability company, its successors and/or assigns (?Investor?). A. Company and Investor are executing and deliv |
|
| December 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2022 Commission File Number: 333-231839 CHINA SXT PHARMACEUTICALS, INC. (Translation of registrant’s name into English) 178 Taidong Rd North, Taizhou Jiangsu, China (Address of princip |
|
| October 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2022 Commission File Number: 333-231839 CHINA SXT PHARMACEUTICALS, INC. (Translation of registrant’s name into English) 178 Taidong Rd North, Taizhou Jiangsu, China (Address of principa |
|
| September 27, 2022 |
Form of Voting Agreement, dated September 22, 2022, by and between Zhijun Xiao and Hao Xia Exhibit 4.2 VOTING RIGHTS PROXY AGREEMENT This Voting Rights Proxy Agreement (this ?Agreement?) is entered into as of [ ], 2022 (?Effective Date?), by and between Zhijun Xiao (the ?Shareholder?) and Hao Xia (?Xia?). The Shareholder and Xia are each referred to in this Agreement as a ?Party? and collectively as the ?Parties.? R E C I T A L S A. The Shareholder is a member of China SXT Pharmaceutica |
|
| September 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 Commission File Number: 333-231839 CHINA SXT PHARMACEUTICALS, INC. (Translation of registrant?s name into English) 178 Taidong Rd North, Taizhou Jiangsu, China (Address of princi |
|
| September 27, 2022 |
Form of Voting Agreement, dated September 22, 2022, by and between Zhijun Xiao and Feng Zhou Exhibit 4.1 VOTING RIGHTS PROXY AGREEMENT This Voting Rights Proxy Agreement (this ?Agreement?) is entered into as of [ ], 2022 (?Effective Date?), by and between Zhijun Xiao (the ?Shareholder?) and Feng Zhou Management Limited (?Zhou?). The Shareholder and Zhou are each referred to in this Agreement as a ?Party? and collectively as the ?Parties.? R E C I T A L S A. The Shareholder is a member of |
|
| September 27, 2022 |
Form of SPA, dated September 22, 2022, by and between the Company and Zhijun Xiao Exhibit 10.1 SECURITIES PURCHASE AGREEMENT ?????? This SECURITIES PURCHASE AGREEMENT (the ?Agreement?) is dated as of [?] by and among China SXT Pharmaceuticals, Inc., a British Virgin Islands company, (the ?Company?), and the individual who affixes his signature on the signature page of this Agreement (the ?Purchaser?). ???????(??????????)?[?]?????????????????????????????????????????????????????? |
|
| August 25, 2022 |
SXTC / China SXT Pharmaceuticals Inc / Streeterville Capital LLC - NONE Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* China SXT Pharmaceuticals, Inc. (Name of Issuer) Common stock, $0.08 par value (Title of Class of Securities) G2161P132 (CUSIP Number) August 25, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| July 18, 2022 |
CFO Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Xiaodong Pan, certify that: 1. I have reviewed this annual report on Form 20-F of China SXT Pharmaceuticals, Inc. (the ?Company?); 2. Based on my knowledge, this report does not contain any untrue sta |
|
| July 18, 2022 |
CEO and CFO Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Exhibit 13.1 Certifications Pursuant to 18 U.S.C. Section 1350 Pursuant to U.S.C. Section 1350 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), each of the undersigned officers of China SXT Pharmaceuticals, Inc. (the ?Company?), does hereby certify, to such officer?s knowledge, that: The Annual Report on Form 20-F for the year |
|
| July 18, 2022 |
CEO Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Feng Zhou, certify that: 1. I have reviewed this annual report on Form 20-F of China SXT Pharmaceuticals, Inc. (the ?Company?); 2. Based on my knowledge, this report does not contain any untrue statem |
|
| July 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1 |
|
| July 18, 2022 |
Amended and Restated Memorandum and Articles of Association, effective on May 17, 2022 Exhibit 1.4 BVI COMPANY NUMBER: 1949664 TERRITORY OF THE BRITISH VIRGIN ISLANDS THE BVI BUSINESS COMPANIES ACT, 2004 MEMORANDUM AND ARTICLES OF ASSOCIATION OF China SXT Pharmaceuticals, Inc. Incorporated on the 4th day of July, 2017 Amended and restated on the 17th day of May, 2022 INCORPORATED IN THE BRITISH VIRGIN ISLANDS China SXT Pharmaceuticals, Inc. TERRITORY OF THE BRITISH VIRGIN ISLANDS TH |
|
| May 13, 2022 |
Offer Letter with Mr. Songfan He dated May 10, 2022 Exhibit 10.2 |
|
| May 13, 2022 |
Offer Letter with Mr. Tong Liu dated May 10, 2022 Exhibit 10.1 |
|
| May 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 Commission File Number: 333-231839 CHINA SXT PHARMACEUTICALS, INC. (Translation of registrant?s name into English) 178 Taidong Rd North, Taizhou Jiangsu, China (Address of principal ex |
|
| May 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 Commission File Number: 333-231839 CHINA SXT PHARMACEUTICALS, INC. (Translation of registrant?s name into English) 178 Taidong Rd North, Taizhou Jiangsu, China (Address of principal ex |
|
| March 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2022 Commission File Number: 333-231839 CHINA SXT PHARMACEUTICALS, INC. (Translation of registrant?s name into English) 178 Taidong Rd North, Taizhou Jiangsu, China (Address of principal |
|
| March 16, 2022 |
Form of Convertible Promissory Note Exhibit 10.2 CONVERTIBLE PROMISSORY NOTE March 16, 2022 U.S. $2,804,848.00 FOR VALUE RECEIVED, China SXT Pharmaceuticals, Inc., a British Virgin Islands corporation (?Borrower?), promises to pay to Streeterville Capital, LLC, a Utah limited liability company, or its successors or assigns (?Lender?), $2,804,848.00 and any interest, fees, charges, and late fees accrued hereunder on the date that is |
|
| March 16, 2022 |
Form of Securities Purchase Agreement Exhibit 10.1 Securities Purchase Agreement This Securities Purchase Agreement (this ?Agreement?), dated as of March 14, 2022, is entered into by and between China SXT Pharmaceuticals, Inc., a British Virgin Islands corporation (?Company?), and Streeterville Capital, LLC, a Utah limited liability company, its successors and/or assigns (?Investor?). A. Company and Investor are executing and deliveri |
|
| March 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2022 Commission File Number: 333-231839 CHINA SXT PHARMACEUTICALS, INC. (Translation of registrant?s name into English) 178 Taidong Rd North, Taizhou Jiangsu, China (Address of principal |
|
| March 16, 2022 |
$2,804,848 Unsecured Convertible Promissory Note China SXT Pharmaceuticals, Inc. Filed pursuant to Rule 424(b)(5) Registration No. 333-252664 Prospectus Supplement (To Prospectus dated February 2, 2021, as amended) $2,804,848 Unsecured Convertible Promissory Note China SXT Pharmaceuticals, Inc. China SXT Pharmaceuticals, Inc. (the ?Company? or ?we?) is offering an unsecured convertible promissory note in the original principal amount of $2,804,848 (the ?Note?), convertible int |
|
| March 15, 2022 |
Exhibit 4.2 CHINA SXT PHARMARCEUTICALS, INC. 2022 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are: ? to attract and retain the best available personnel for positions of substantial responsibility, ? to provide additional incentive to Employees, Directors and Consultants, and ? to promote the success of the Company?s business. The Plan permits the grant of Incentive Sto |
|
| March 15, 2022 |
Exhibit 107 Calculation of Filing Fee Tables S-8 (Form Type) CHINA SXT PHARMACEUTICALS, INC. |
|
| March 15, 2022 |
As filed with the Securities and Exchange Commission on March 15, 2022 As filed with the Securities and Exchange Commission on March 15, 2022 Registration No. |
|
| February 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2022 Commission File Number: 333-231839 CHINA SXT PHARMACEUTICALS, INC. (Translation of registrant?s name into English) 178 Taidong Rd North, Taizhou Jiangsu, China (Address of princip |
|
| January 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2022 Commission File Number: 333-231839 CHINA SXT PHARMACEUTICALS, INC. (Translation of registrant?s name into English) 178 Taidong Rd North, Taizhou Jiangsu, China (Address of principa |
|
| January 31, 2022 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the ?Agreement?), is entered into as of January 31, 2022, (the ?Effective Date?), by and between China SXT Pharmaceuticals, Inc., incorporated under the laws of the British Virgin Islands (the ?Company?), and Xiaodong Pan, an individual (the ?Chief Financial Officer (CFO)?). Except with respect to the direct employment of the CFO by the |
|
| January 21, 2022 |
Exhibit 1.1 CHINA SXT PHARMACEUTICALS, INC. UNDERWRITING AGREEMENT January 18, 2022 Aegis Capital Corp. 810 7th Avenue New York, New York 10019 Ladies and Gentlemen: The undersigned, China SXT Pharmaceuticals, Inc., a British Virgin Islands corporation, (collectively with its Subsidiaries (as defined below) the ?Company?), hereby confirms its agreement (this ?Agreement?) with Aegis Capital Corp. ( |
|
| January 21, 2022 |
Exhibit 99.2 China SXT Pharmaceuticals, Inc. Prices $3.5 Million Underwritten Public Offering of Ordinary Shares and Pre-Funded Warrants to Purchase Ordinary Shares TAIZHOU, China, Jan. 18, 2022 (GLOBE NEWSWIRE) - China SXT Pharmaceuticals, Inc. (?SXTC? or the ?Company?), (NASDAQ: SXTC), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales o |
|
| January 21, 2022 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Ordinary Shares, $0.004 par value per share, of China SXT Pharmaceuticals, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13G. January 21, 2022 LIND GLOBAL FUND II LP By: Lind Global Pa |
|
| January 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2022 Commission File Number: 333-231839 CHINA SXT PHARMACEUTICALS, INC. (Translation of registrant?s name into English) 178 Taidong Rd North, Taizhou Jiangsu, China (Address of principa |
|
| January 21, 2022 |
Exhibit 4.1 WARRANT AGENT AGREEMENT This WARRANT AGENT AGREEMENT (this ?Warrant Agreement?) dated as of January 18, 2022 (the ?Issuance Date?) is between China SXT Pharmaceuticals, Inc., a British Virgin Islands corporation (the ?Company?), and TranShare Corporation (the ?Warrant Agent?). WHEREAS, pursuant to the terms of that certain Underwriting Agreement (?Underwriting Agreement?), dated Januar |
|
| January 21, 2022 |
Exhibit 99.1 China SXT Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Ordinary Shares and Pre-Funded Warrants to Purchase Ordinary Shares TAIZHOU, China, Jan. 14, 2022 /PRNewswire/ - China SXT Pharmaceuticals, Inc. (?SXTC? or the ?Company?), (NASDAQ: SXTC), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Tra |
|
| January 21, 2022 |
Exhibit 99.3 China SXT Pharmaceuticals, Inc. Announces Successful Closing of $4.1 Million Follow-on Underwritten Offering of Ordinary Shares and Pre-Funded Warrants With Simultaneous Exercise of the Over-Allotment TAIZHOU, China, Jan. 20, 2022 (GLOBE NEWSWIRE) - China SXT Pharmaceuticals, Inc. (?SXTC? or the ?Company?), (NASDAQ: SXTC), a specialty pharmaceutical company focusing on the research, d |
|
| January 21, 2022 |
SXTC / China SXT Pharmaceuticals Inc / Lind Global Fund II LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* China SXT Pharmaceuticals, Inc. (Name of Issuer) Ordinary Shares, $0.004 par value per share (Title of Class of Securities) G2161P108 (CUSIP Number) January 20, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to desi |
|
| January 20, 2022 |
8,285,260 Ordinary Shares 11,521,500 Pre-Funded Warrants China SXT Pharmaceuticals, Inc. Filed pursuant to Rule 424(b)(5) Registration No. 333-252664 Prospectus Supplement (To Prospectus dated February 2, 2021, as amended) 8,285,260 Ordinary Shares 11,521,500 Pre-Funded Warrants China SXT Pharmaceuticals, Inc. We are offering 8,285,260 ordinary shares, US$0.004 par value per share (?Ordinary Shares?) at a price of US$0.18 per share, and 11,521,500 pre-funded warrants (each a ?Pre-fund |
|
| January 18, 2022 |
SUBJECT TO COMPLETION, DATED jANUARY 18, 2022 Filed pursuant to Rule 424(b)(5) Registration No. 333-252664 The information in this prospectus supplement is not complete and may be changed. This prospectus supplement is not an offer to sell these securities, and we are not soliciting offers to buy these securities, in any state or other jurisdiction where the offer or sale is not permitted. SUBJECT TO COMPLETION, DATED jANUARY 18, 2022 Prospec |
|
| January 14, 2022 |
Exhibit 99.1 CHINA SXT PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED SEPTEMBER 30, 2021 AND 2020 (UNAUDITED) CHINA SXT PHARMACEUTICALS, INC. INDEX TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Condensed Consolidated Financial Statements Condensed Consolidated Balance Sheets as of September 30, 2021 (Unaudited) and March 31, 2021 F-2 Condensed Consolida |
|
| January 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the six-month period ended September 30, 2021 CHINA SXT PHARMACEUTICALS, INC. (Translation of registrant?s name into English) 178 Taidong Rd North, Taizhou Jiangsu, China (Address of principal executive off |
|
| August 27, 2021 |
Exhibit 4.2 CHINA SXT PHARMARCEUTICALS, INC. 2021 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are: ? to attract and retain the best available personnel for positions of substantial responsibility, ? to provide additional incentive to Employees, Directors and Consultants, and ? to promote the success of the Company?s business. The Plan permits the grant of Incentive Sto |
|
| August 27, 2021 |
As filed with the Securities and Exchange Commission on August 27, 2021 As filed with the Securities and Exchange Commission on August 27, 2021 Registration No. |
|
| August 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1 |
|
| August 13, 2021 |
CEO and CFO Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Exhibit 13.1 Certifications Pursuant to 18 U.S.C. Section 1350 Pursuant to U.S.C. Section 1350 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), each of the undersigned officers of China SXT Pharmaceuticals, Inc. (the ?Company?), does hereby certify, to such officer?s knowledge, that: The Annual Report on Form 20-F for the year |
|
| August 13, 2021 |
Amended and Restated Memorandum and Articles of Association, effective on February 21, 2021 Exhibit 1.3 BVI COMPANY NUMBER: 1949664 TERRITORY OF THE BRITISH VIRGIN ISLANDS THE BVI BUSINESS COMPANIES ACT, 2004 MEMORANDUM AND ARTICLES OF ASSOCIATION OF China SXT Pharmaceuticals, Inc. Incorporated on the 4th day of July, 2017 Amended and restated on the 18th day of February 2021 INCORPORATED IN THE BRITISH VIRGIN ISLANDS China SXT Pharmaceuticals, Inc. TERRITORY OF THE BRITISH VIRGIN ISLAND |
|
| August 13, 2021 |
CEO Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Feng Zhou, certify that: 1. I have reviewed this annual report on Form 20-F of China SXT Pharmaceuticals, Inc. (the ?Company?); 2. Based on my knowledge, this report does not contain any untrue statem |
|
| August 13, 2021 |
Exhibit 4.6 CHINA SXT PHARMARCEUTICALS, INC. 2021 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are: ? to attract and retain the best available personnel for positions of substantial responsibility, ? to provide additional incentive to Employees, Directors and Consultants, and ? to promote the success of the Company?s business. The Plan permits the grant of Incentive Sto |
|
| August 13, 2021 |
CFO Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Feng Zhou, certify that: 1. I have reviewed this annual report on Form 20-F of China SXT Pharmaceuticals, Inc. (the ?Company?); 2. Based on my knowledge, this report does not contain any untrue statem |
|
| August 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form N-SAR ? Form N-CSR For Period Ended: March 31, 2021 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| May 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2021 Commission File Number: 333-231839 CHINA SXT PHARMACEUTICALS, INC. (Translation of registrant?s name into English) 178 Taidong Rd North, Taizhou Jiangsu, China (Address of principal ex |
|
| May 26, 2021 |
Director Offer Letter of Xiaodong Ji, dated May 22, 2021 Exhibit 4.1 CHINA SXT PHARMACEUTICALS, INC. 178 Taidong Rd North, Taizhou Jiangsu, China May 22, 2021 Re: Director Offer Letter Dear Mr. Xiaodong Ji CHINA SXT PHARMACEUTICALS, INC., a British Virgin Islands exempt company (the ?Company?), is pleased to offer you a position as a member of its Board of Directors (the ?Board?). We believe your background and experience will be a significant asset to |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2021 Commission File Number: 333-231839 CHINA SXT PHARMACEUTICALS, INC. (Translation of registrant?s name into English) 178 Taidong Rd North, Taizhou Jiangsu, China (Address of principal ex |
|
| April 8, 2021 |
Current Report of Foreign Issuer - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2021 Commission File Number: 333-231839 CHINA SXT PHARMACEUTICALS, INC. (Translation of registrant?s name into English) 178 Taidong Rd North, Taizhou Jiangsu, China (Address of principal |
|
| March 3, 2021 |
Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2021 Commission File Number: 001-38773 CHINA SXT PHARMACEUTICALS, INC. (Translation of registrant?s name into English) 178 Taidong Rd North, Taizhou Jiangsu, China (Address of principal e |
|
| March 3, 2021 |
Exhibit 99.1 CHINA SXT PHARMACEUTICALS, INC. 178 Taidong Road North Taizhou, Jiangsu People’s Republic of China NOTICE OF 2021 ANNUAL MEETING OF SHAREHOLDERS To Be Held at 9:30 A.M. EST on March 31, 2021 To the Shareholders of China SXT Pharmaceuticals, Inc.: This proxy statement is furnished in connection with the solicitation of proxies by the Board of Directors (the “Board” ) of China SXT Pharm |
|
| March 3, 2021 |
Exhibit 99.2 CHINA SXT PHARMACEUTICALS, INC. 178 Taidong Road North, Taizhou, Jiangsu, People?s Republic of China NOTICE OF ANNUAL MEETING OF STOCKHOLDERS To Be Held at 9:30 A.M. EST on March 31, 2021 (Record Date ? February 22, 2021) THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned hereby appoints Feng Zhou, as proxy of the undersigned, with full power to appoint his su |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934(Amendment No. |
|
| February 16, 2021 |
Form of Voting Agreement, dated February 8, 2021, by and between Xiaodong Ji and Feng Zhou Exhibit 4.1 VOTING RIGHTS PROXY AGREEMENT This Voting Rights Proxy Agreement (this ?Agreement?) is entered into as of [ ], 2021 (?Effective Date?), by and between Xiaodong Ji (the ?Shareholder?) and Feng Zhou (?Zhou?). The Shareholder and Zhou are each referred to in this Agreement as a ?Party? and collectively as the ?Parties.? RECITALS A. The Shareholder is a member of China SXT Pharmaceuticals, |
|
| February 16, 2021 |
Form of SPA, dated February 8, 2021, by and between the Company and Xiaodong Ji Exhibit 10.1 SECURITIES PURCHASE AGREEMENT ?????? This SECURITIES PURCHASE AGREEMENT (the ?Agreement?) is dated as of [?] by and among China SXT Pharmaceuticals, Inc., a British Virgin Islands company, (the ?Company?), and individual who affixes its signature on the signature page of this Agreement (each, a ?Purchaser?; collectively, the ?Purchaser?). ???????(??????????)?[?] ?????????????????????? |
|
| February 16, 2021 |
Joint Filing Statement Statement Pursuant to Rule 13d-1(k)(1) Exhibit 1 Joint Filing Statement Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to file a joint statement on Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the Common Stock, $0. |
|
| February 16, 2021 |
Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2021 Commission File Number: 333-231839 CHINA SXT PHARMACEUTICALS, INC. (Translation of registrant?s name into English) 178 Taidong Rd North, Taizhou Jiangsu, China (Address of princip |
|
| February 11, 2021 |
China SXT Pharmaceuticals, Inc. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* China SXT Pharmaceuticals, Inc. (Name of Issuer) Ordinary Shares, par value $0.001 per share (Title of Class of Securities) G2161P108 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 9, 2021 |
China SXT Pharmaceuticals, Inc. 178 Taidong Road North Taizhou, Jiangsu People?s Republic of China 86-52386298290 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Deanna Virginio Office of Life Sciences February 9, 2021 Re: China SXT Pharmaceuticals, Inc. Registration Statement on Form F-3 Filed February 3, 202 |
|
| February 3, 2021 |
Form of Employment Agreement dated February 1, 2021, by and between the Company and Mr. Wang Lee Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”), is entered into as of February 1, 2021 (the “Effective Date”), by and between China SXT Pharmaceuticals, Inc., incorporated under the laws of the British Virgin Islands (the “Company”), and Wang L. Lee, an individual (the “Chief Financial Officer (CFO)”). Except with respect to the direct employment of the CFO by the Co |
|
| February 3, 2021 |
Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2021 Commission File Number: 333-231839 CHINA SXT PHARMACEUTICALS, INC. (Translation of registrant’s name into English) 178 Taidong Rd North, Taizhou Jiangsu, China (Address of princip |
|
| February 2, 2021 |
Exhibit 4.5 CHINA SXT PHARMACEUTICALS, INC. (the “Issuer”) AND [TRUSTEE] (the “Trustee”) INDENTURE Dated as of [●], 20[●] Senior Debt Securities TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities |
|
| February 2, 2021 |
As filed with the Securities and Exchange Commission on February 2, 2021 Registration No. |
|
| February 2, 2021 |
Exhibit 4.6 CHINA SXT PHARMACEUTICALS, INC. Issuer AND [TRUSTEE] Trustee INDENTURE Dated as of [●], 20[●] Subordinated Debt Securities TABLE OF CONTENTS ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms. 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities. 4 Section 2.02 Form of Securities and Trustee’ |
|
| January 28, 2021 |
Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the six-month period ended September 30, 2020 CHINA SXT PHARMACEUTICALS, INC. (Translation of registrant’s name into English) 178 Taidong Rd North, Taizhou Jiangsu, China (Address of principal executive off |
|
| January 28, 2021 |
Settlement Agreement with FT Global, dated January 18, 2021 EX-4.1 2 ea133557ex4-1chinasxt.htm SETTLEMENT AGREEMENT, DATED JANUARY 18, 2021, BY AND BETWEEN FT GLOBAL CAPITAL, INC. AND THE COMPANY Exhibit 4.1 SETTLEMENT AGREEMENT This Settlement Agreement is dated January 18, 2021 (the “Settlement Agreement”), by and between China SXT Pharmaceuticals, Inc. (the “Company”), a British Virgin Islands company, FT Global Capital, Inc. (“FT”), a Georgia company ( |
|
| January 28, 2021 |
EX-99.1 4 ea133557ex99-1chinasxt.htm UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2020 AND FOR THE SIX MONTHS ENDED SEPTEMBER 30, 2020 AND 2019 Exhibit 99.1 CHINA SXT PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED SEPTEMBER 30, 2020 AND 2019 (UNAUDITED) CHINA SXT PHARMACEUTICALS, INC. INDEX TO CONDENSED CONSOLIDATED F |
|
| January 28, 2021 |
Form of Warrant Issued in Connection with the Settlement Agreement with FT Global Exhibit 4.2 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR T |
|
| December 3, 2020 |
Form of Voting Agreement, dated November 24, 2020, by and between Xing Yuan and Feng Zhou Exhibit 4.1 VOTING RIGHTS PROXY AGREEMENT This Voting Rights Proxy Agreement (this “Agreement”) is entered into as of November 24, 2020 (“Effective Date”), by and between Xing Yuan (“Yuan”) and Feng Zhou (“Zhou”). Yuan and Zhou are each referred to in this Agreement as a “Party” and collectively as the “Parties.” RECITALS A. Xing Yuan is a member of China SXT Pharmaceuticals, Inc, a British Virgin |
|
| December 3, 2020 |
Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2020 Commission File Number: 333-231839 CHINA SXT PHARMACEUTICALS, INC. (Translation of registrant’s name into English) 178 Taidong Rd North, Taizhou Jiangsu, China (Address of princip |
|
| December 3, 2020 |
Form of SPA, dated November 24, 2020, by and between the Company and Xing Yuan Exhibit 10.1 SECURITIES PURCHASE AGREEMENT 证券购买协议 This SECURITIES PURCHASE AGREEMENT (the “Agreement”) is dated as of [●] by and among China SXT Pharmaceuticals, Inc., a British Virgin Islands company, (the “Company”), and individual who affixes its signature on the signature page of this Agreement (each, a “Purchaser”; collectively, the “Purchaser”). 本证券购买协议(“本协议”或“协议”)于[●]，由江苏苏轩堂药业有限公司，一家英属维京群岛公 |
|
| July 31, 2020 |
CEO and CFO Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Exhibit 13.1 Certifications Pursuant to 18 U.S.C. Section 1350 Pursuant to U.S.C. Section 1350 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), each of the undersigned officers of China SXT Pharmaceuticals, Inc. (the “Company”), does hereby certify, to such officer’s knowledge, that: The Annual Report on Form 20-F for the year |
|
| July 31, 2020 |
CEO Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Feng Zhou, certify that: 1. I have reviewed this annual report on Form 20-F of China SXT Pharmaceuticals, Inc. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statem |
|
| July 31, 2020 |
Amended and Restated Memorandum and Articles of Association, effective on March 30, 2020 Exhibit 1.2 BVI COMPANY NUMBER: 1949664 TERRITORY OF THE BRITISH VIRGIN ISLANDS THE BVI BUSINESS COMPANIES ACT, 2004 Memorandum and Articles of Association of China SXT Pharmaceuticals, Inc. Incorporated on the 4th day of July, 2017 Amended and restated on the 30th day of March 2020 INCORPORATED IN THE BRITISH VIRGIN ISLANDS China SXT Pharmaceuticals, Inc. TERRITORY OF THE BRITISH VIRGIN ISLANDS T |
|
| July 31, 2020 |
CFO Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Feng Zhou, certify that: 1. I have reviewed this annual report on Form 20-F of China SXT Pharmaceuticals, Inc. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statem |
|
| July 31, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1 |
|
| July 10, 2020 |
Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2020 Commission File Number: 333-231839 CHINA SXT PHARMACEUTICALS, INC. (Translation of registrant’s name into English) 178 Taidong Rd North, Taizhou Jiangsu, China (Address of principal e |
|
| May 22, 2020 |
Exhibit 99.1 CHINA SXT PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) FOR THE SIX MONTHS ENDED SEPTEMBER 30, 2019 AND 2018 TABLE OF CONTENTS Condensed Consolidated Interim Financial Statements Condensed Consolidated Balance Sheets as of September 30, 2019 (UNAUDITED) and March 31, 2019 2 Condensed Consolidated Statements of Operation and Comprehensive Income |
|
| May 22, 2020 |
Current Report of Foreign Issuer - AMENDMENT TO REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K/A Amendment No. 1 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2020 Commission File Number: 333-231839 CHINA SXT PHARMACEUTICALS, INC. (Translation of registrant’s name into English) 178 Taidong Rd North, Taizhou Jiangsu, China (Addre |
|
| April 22, 2020 |
EX-99.1 2 ea120894ex99-1chinasxt.htm CHINA SXT PHARMACEUTICALS, INC. UNAUDITED FINANCIAL RESULTS FOR THE SIX MONTHS ENDED SEPTEMBER 30, 2019 AND 2018 Exhibit 99.1 CHINA SXT PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) FOR THE SIX MONTHS ENDED SEPTEMBER 30, 2019 AND 2018 TABLE OF CONTENTS Condensed Consolidated Interim Financial Statements Condensed Consolid |
|
| April 22, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2020 Commission File Number: 333-231839 CHINA SXT PHARMACEUTICALS, INC. (Translation of registrant’s name into English) 178 Taidong Rd North, Taizhou Jiangsu, China (Address of principal |
|
| March 31, 2020 |
SXTC / China SXT Pharmaceuticals, Inc. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2020 Commission File Number: 333-231839 CHINA SXT PHARMACEUTICALS, INC. (Translation of registrant’s name into English) 178 Taidong Rd North, Taizhou Jiangsu, China (Address of principal |
|
| March 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2020 Commission File Number: 333-231839 CHINA SXT PHARMACEUTICALS, INC. (Translation of registrant’s name into English) 178 Taidong Rd North, Taizhou Jiangsu, China (Address of principal |
|
| March 10, 2020 |
Exhibit 99.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”), is entered into as of March 8, 2020 (the “Effective Date”), by and between China SXT Pharmaceuticals, Inc., incorporated under the laws of the British Virgin Islands (the “Company”), and Peter Chan, an individual (the “Chief Financial Officer (CFO)”). Except with respect to the direct employment of the CFO by the Compan |
|
| March 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2020 Commission File Number: 333-231839 CHINA SXT PHARMACEUTICALS, INC. (Translation of registrant’s name into English) 178 Taidong Rd North, Taizhou Jiangsu, China (Address of principal |
|
| March 4, 2020 |
Exhibit 10.1 LEAK OUT AGREEMENT March 3, 2020 China SXT Pharmaceuticals, Inc. 178 Taidong Rd North Taizhou, Jiangsu China Re: Agreement Ladies and Gentlemen: Reference is hereby made to (a) that certain Securities Purchase Agreement, dated as of April 16, 2019 (as amended, restated or otherwise modified from time to time prior to the date hereof, the “Securities Purchase Agreement”), by and among |
|
| February 14, 2020 |
SXTC / China SXT Pharmaceuticals, Inc. / Ayrton Capital LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934(Amendment No. |
|
| February 14, 2020 |
Joint Filing Statement Statement Pursuant to Rule 13d-1(k)(1) Exhibit 1 Joint Filing Statement Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to file a joint statement on Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the Common Stock, $0. |
|
| February 7, 2020 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* China SXT Pharmaceuticals, Inc. (Name of Issuer) Ordinary Shares, par value $0.001 per share (Title of Class of Securities) G2161P108 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| January 31, 2020 |
Exhibit 99.1 CHINA SXT PHARMACEUTICALS, INC. 178 Taidong Road North Taizhou, Jiangsu People’s Republic of China NOTICE OF 2020 ANNUAL MEETING OF SHAREHOLDERS To Be Held at 9:30 a.m. on March 10, 2020 Eastern Standard Time To the Shareholders of China SXT Pharmaceuticals, Inc.: This proxy statement is furnished in connection with the solicitation of proxies by the Board of Directors (the “Board” ) |
|
| January 31, 2020 |
Exhibit 99.2 CHINA SXT PHARMACEUTICALS, INC. 178 Taidong Road North, Taizhou, Jiangsu, People’s Republic of China NOTICE OF ANNUAL MEETING OF STOCKHOLDERS To Be Held at 9:30 a.m. on March 10, 2020 Eastern Standard Time (Record Date – January 15, 2020) THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned hereby appoints Feng Zhou, as proxy of the undersigned, with full power |
|
| January 31, 2020 |
SXTC / China SXT Pharmaceuticals, Inc. 6-K - Current Report of Foreign Issuer - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2020 Commission File Number: 001-38773 CHINA SXT PHARMACEUTICALS, INC. (Translation of registrant’s name into English) 178 Taidong Rd North, Taizhou Jiangsu, China (Address of principal |
|
| December 16, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2019 Commission File Number: 333-231839 CHINA SXT PHARMACEUTICALS, INC. (Translation of registrant’s name into English) 178 Taidong Rd North, Taizhou Jiangsu, China (Address of princip |
|
| December 16, 2019 |
Exhibit 10.2 FORM OF LOCK-UP AGREEMENT December 13, 2019 China SXT Pharmaceuticals, Inc. 178 Taidong Rd North Taizhou, Jiangsu China Re: Pre-Delivered Shares Ladies and Gentlemen: Reference is hereby made to (a) that certain Securities Purchase Agreement, dated as of April 16, 2019 (as amended, restated or otherwise modified from time to time prior to the date hereof, the “Securities Purchase Agre |
|
| December 16, 2019 |
Exhibit 10.3 CHINA SXT PHARMACEUTICALS, INC. 178 Taidong Rd North, Taizhou Jiangsu Province, China December 13, 2019 [INVESTOR] [INVESTOR’S ADDRESS] Dear Sirs: Reference is hereby made to (a) that certain Securities Purchase Agreement, dated as of April 16, 2019 (as amended, restated or otherwise modified from time to time prior to the date hereof, the “SPA”), by and among CHINA SXT PHARMACEUTICAL |
|
| December 16, 2019 |
Exhibit 10.4 FORM OF MUTUAL RELEASE TO ALL TO WHOM THESE PRESENTS SHALL COME OR MAY CONCERN, KNOW THAT: Reference is hereby made to (a) that certain Securities Purchase Agreement, dated as of April 16, 2019 (as amended, restated or otherwise modified from time to time prior to the date hereof, the “Securities Purchase Agreement”), by and among CHINA SXT PHARMACEUTICALS, INC., a company organized u |
|
| December 16, 2019 |
Exhibit 10.1 FORM OF FORBEARANCE AND AMENDMENT AGREEMENT This Forbearance and Amendment Agreement (“Agreement”) is made and entered into this 13th day of December, 2019, by and between, [INVESTOR] (the “Investor”) and CHINA SXT PHARMACEUTICALS, INC., a company organized under the laws of the British Virgin Islands (the “Company”) (collectively, the “Parties”). WHEREAS, the Parties refer herein to |
|
| November 5, 2019 |
6,288,752 Ordinary Shares China SXT Pharmaceuticals, Inc. Filed Pursuant to 424(b)(8) Registration No. 333-231839 PROSPECTUS 6,288,752 Ordinary Shares China SXT Pharmaceuticals, Inc. This prospectus relates to the resale, from time to time, by the selling shareholders identified in this prospectus under the caption “Selling Shareholders,” of up to 6,288,752 shares of our Ordinary Shares, par value $0.001 per share, issuable upon conversion, repayment or |
|
| August 19, 2019 |
SXTC / China SXT Pharmaceuticals, Inc. 20-F/A - - AMENDMENT NO. 1 TO FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F/A Amendment No. 1 ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES |
|
| August 19, 2019 |
Supplement Agreement No.2 to the Limited Partnership Admission Agreement * EX-4.16 5 f20f2019a1ex4-16chinasxt.htm SUPPLEMENT AGREEMENT NO.2 TO THE LIMITED PARTNERSHIP ADMISSION AGREEMENT Exhibit 4.16 English Translation Supplement Agreement No. 2 to Limited Partnership Admission Agreement Huangshan Panjie Investment Management Co., Ltd. Jiangsu Su Xuan Tang Pharmaceutical Co. Ltd. 1 Party A: Huangshan Panjie Investment Management Co., Ltd Legal Representative: LI, Ren Yo |
|
| August 19, 2019 |
Supplement Agreement No.1 to the Limited Partnership Admission Agreement * EX-4.15 4 f20f2019a1ex4-15chinasxt.htm SUPPLEMENT AGREEMENT NO.1 TO THE LIMITED PARTNERSHIP ADMISSION AGREEMENT Exhibit 4.15 English Translation Supplement Agreement No. 1 to Huangshan Panjie Investment Fund LLP Limited Partnership Admission Agreement This Huangshan Panjie Investment Fund LLP Limited Partnership Admission Agreement was signed by the following partners on June 10, 2019 in Huangshan |
|
| August 19, 2019 |
EX-4.14 3 f20f2019a1ex4-14chinasxt.htm SUPPLEMENT AGREEMENT TO THE LIMITED PARTNERSHIP AGREEMENT Exhibit 4.14 English Translation Supplement Agreement to Huangshan Panjie Investment Fund LLP Limited Partnership Agreement June, 2019 1 Supplement Agreement to the Huangshan Panjie Investment Fund LLP Limited Partnership Agreement The Huangshan Panjie Investment Fund LLP Limited Partnership Admission |
|
| August 19, 2019 |
CFO Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 * Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Yao Shi, certify that: 1. I have reviewed this annual report on Form 20-F of China SXT Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material |
|
| August 19, 2019 |
CEO Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 * Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Feng Zhou, certify that: 1. I have reviewed this annual report on Form 20-F of China SXT Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a materia |
|
| August 19, 2019 |
Limited Partnership Admission Agreement * EX-4.13 2 f20f2019a1ex4-13chinasxt.htm LIMITED PARTNERSHIP ADMISSION AGREEMENT Exhibit 4.13 English Translation Huangshan Panjie Investment Fund LLP Limited Partnership Admission Agreement This agreement was signed by and among the following parties on June 10, 2019 at Huangshan High-tech Industrial Development Zone (former Huangshan Economic Development Zone), Anhui, China: New Limited Partner: J |
|
| August 15, 2019 |
CEO Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 * Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Feng Zhou, certify that: 1. I have reviewed this annual report on Form 20-F of China SXT Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a materia |
|
| August 15, 2019 |
CFO Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 * Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Yao Shi, certify that: 1. I have reviewed this annual report on Form 20-F of China SXT Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material |
|
| August 15, 2019 |
CEO and CFO Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 * Exhibit 13.1 Certifications Pursuant to 18 U.S.C. Section 1350 Pursuant to U.S.C. Section 1350 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), each of the undersigned officers of China SXT Pharmaceuticals, Inc. (the “Company”), does hereby certify, to such officer’s knowledge, that: The Annual Report on Form 20-F for the year |
|
| August 15, 2019 |
SXTC / China SXT Pharmaceuticals, Inc. 20-F - - ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1 |
|
| July 31, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2019. Commission File Number: 333-231839 CHINA SXT PHARMACEUTICALS, INC. (Translation of registrant’s name into English) 178 Taidong Rd North, Taizhou Jiangsu, China (Address of principal |
|
| July 31, 2019 |
SXTC / China SXT Pharmaceuticals, Inc. NT 20-F - - NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☒ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2019 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| June 25, 2019 |
SXTC / China SXT Pharmaceuticals, Inc. CORRESP - - China SXT Pharmaceuticals, Inc. 178 Taidong Rd North, Taizhou Jiangsu, China VIA EDGAR June 25, 2019 U.S. Securities and Exchange Commission 100 F Street, N.E. Mail Stop 3233 Washington, D.C. 20549 Attn: Ada D. Sarmento Re: China SXT Pharmaceuticals, Inc. Registration Statement on Form F-1/A Initially Filed June 21, 2019 File No. 333-231839 Dear Ms. Sarmento: Pursuant to Rule 461 under the Securit |
|
| June 21, 2019 |
SXTC / China SXT Pharmaceuticals, Inc. F-1/A - - AMENDMENT NO.1 TO FORM F-1 As filed with the Securities and Exchange Commission on June 21, 2019 Registration No. |
|
| June 21, 2019 |
Exhibit 4.10 EXECUTION COPY NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION |
|
| June 21, 2019 |
Exhibit 22.1 List of Subsidiaries of China SXT Pharmaceuticals, Inc. Name Country of Incorporation China SXT Group Limited Hong Kong Taizhou Suxuantang Biotechnology Co. People’s Republic of China Jiangsu Suxuantang Pharmaceutical Co., Ltd People’s Republic of China |
|
| June 21, 2019 |
Exhibit 4.9 EXECUTION COPY NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION |
|
| June 21, 2019 |
Exhibit 4.8 EXECUTION COPY NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION |
|
| June 21, 2019 |
Exhibit 4.5 EXECUTION COPY THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE APPLICABLE STATE SECURITIES LAWS, AND MAY NOT BE OFFERED OR SOLD IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND SUCH STATE SECURITIES LAWS, OR AN EXEMPTION FROM REGISTRATION THEREUNDER, IN EACH CASE, TO THE EXTENT APPLICABLE HERETO. SECURED PROMISSO |
|
| June 21, 2019 |
Exhibit 4.11 EXECUTION COPY NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION |
|
| June 21, 2019 |
Exhibit 4.1 EXECUTION COPY NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION |
|
| June 21, 2019 |
Exhibit 10.4 EXECUTION COPY NOTE PURCHASE AGREEMENT NOTE PURCHASE AGREEMENT (the “Agreement”), dated as of May 2, 2019, by and among China SXT Pharmaceuticals, Inc., a company organized under the laws of the British Virgin Islands with offices located at 178 Taidong Rd North, Taizhou, Jiangsu, China (the “Company”) and the investor signatory hereto (the “Investor”). WHEREAS: A. Prior to the date h |
|
| June 21, 2019 |
Exhibit 4.2 EXECUTION COPY NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION |
|
| June 21, 2019 |
Exhibit 10.3 EXECUTION COPY REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of May 2, 2019, is by and among China SXT Pharmaceuticals, Inc., a company organized under the laws of the British Virgin Islands with offices located at 178 Taidong Rd North, Taizhou, Jiangsu, China (the “Company”), and the undersigned buyers (each, a “Buyer,” and collectively |
|
| June 21, 2019 |
Exhibit 4.4 EXECUTION COPY NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION |
|
| June 21, 2019 |
Exhibit 4.7 EXECUTION COPY NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION |
|
| June 21, 2019 |
Exhibit 4.6 EXECUTION COPY THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE APPLICABLE STATE SECURITIES LAWS, AND MAY NOT BE OFFERED OR SOLD IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND SUCH STATE SECURITIES LAWS, OR AN EXEMPTION FROM REGISTRATION THEREUNDER, IN EACH CASE, TO THE EXTENT APPLICABLE HERETO. SECURED PROMISSO |
|
| June 21, 2019 |
Exhibit 4.3 EXECUTION COPY NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION |
|
| June 21, 2019 |
Exhibit 4.12 EXECUTION COPY NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION |
|
| June 21, 2019 |
Exhibit 10.6 EXECUTION COPY MASTER NETTING AGREEMENT MASTER NETTING AGREEMENT (the “Agreement”), dated as May 2, 2019, by and among China SXT Pharmaceuticals, Inc., a company organized under the laws of the British Virgin Islands with offices located at 178 Taidong Rd North, Taizhou, Jiangsu, China (the “Company”) and the investor signatory hereto (the “Investor”, and together with the Company, th |
|
| June 21, 2019 |
Exhibit 10.7 EXECUTION COPY MASTER NETTING AGREEMENT MASTER NETTING AGREEMENT (the “Agreement”), dated as of May 2, 2019, by and among China SXT Pharmaceuticals, Inc., a company organized under the laws of the British Virgin Islands with offices located at 178 Taidong Rd North, Taizhou, Jiangsu, China (the “Company”) and the investor signatory hereto (the “Investor”, and together with the Company, |
|
| June 21, 2019 |
Exhibit 10.5 EXECUTION COPY NOTE PURCHASE AGREEMENT NOTE PURCHASE AGREEMENT (the “Agreement”), dated as of May 2, 2019, by and among China SXT Pharmaceuticals, Inc., a company organized under the laws of the British Virgin Islands with offices located at 178 Taidong Rd North, Taizhou, Jiangsu, China (the “Company”) and the investor signatory hereto (the “Investor”). WHEREAS: A. Prior to the date h |
|
| June 21, 2019 |
SXTC / China SXT Pharmaceuticals, Inc. CORRESP - - China SXT Pharmaceuticals, Inc. 178 Taidong Rd North, Taizhou Jiangsu, China June 21, 2019 Via Edgar Ms. Ada D. Sarmento Division of Corporation Finance Office of Health & Insurance U.S. Securities and Exchange Commission Re: China SXT Pharmaceuticals, Inc. Registration Statement on Form F-1 Filed on May 30, 2019 File No. 333-231830 Dear Ms. Ada: This letter is in response to the letter dated June |
|
| May 30, 2019 |
As filed with the Securities and Exchange Commission on May 30, 2019 Registration No. |
|
| May 8, 2019 |
SXTC / China SXT Pharmaceuticals, Inc. / Ayrton Capital LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* China SXT Pharmaceuticals, Inc. (Name of Issuer) Ordinary Shares, $0.001 par value per share (Title of Class of Securities) G2161P108 (CUSIP Number) May 2, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| May 8, 2019 |
Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Ordinary Shares, $0. |
|
| May 3, 2019 |
Form of Series B Senior Secured Convertible Note, as amended Exhibit 4.2 EXECUTION COPY NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION |
|
| May 3, 2019 |
Exhibit 10.1 EXECUTION COPY AMENDMENT NO. 1 TO SECURITIES PURCHASE AGREEMENT This AMENDMENT NO. 1, dated as of May 2, 2019 (this “Amendment”), to the SECURITIES PURCHASE AGREEMENT (the “Securities Purchase Agreement”), dated as of April 16, 2019, by and among China SXT Pharmaceuticals, Inc., a company organized under the laws of the British Virgin Islands with offices located at 178 Taidong Rd Nor |
|
| May 3, 2019 |
Form of Series A Senior Convertible Note, as amended. EX-4.1 2 f6k050319ex4-1chinasxt.htm FORM OF SERIES A SENIOR CONVERTIBLE NOTET, AS AMENDED Exhibit 4.1 EXECUTION COPY NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FO |
|
| May 3, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2019. Commission File Number: 333-221899 CHINA SXT PHARMACEUTICALS, INC. (Translation of registrant’s name into English) 178 Taidong Rd North, Taizhou Jiangsu, China (Address of principal e |
|
| April 17, 2019 |
Exhibit 10.5 SHAREHOLDER PLEDGE AGREEMENT SHAREHOLDER PLEDGE AGREEMENT (this “Agreement”), dated as of April , 2019, made by Feng Zhou Management Limited, a British Virgin Islands company wholly owned by Feng Zhou with the address at Sertus Chambers PO Box 905 Quisticky Building Road Town Tortola British Virgin Islands (collectively, the “Pledgor”), China SXT Pharmaceuticals, Inc., a company organ |
|
| April 17, 2019 |
Exhibit 10.3 EXECUTION COPY NOTE PURCHASE AGREEMENT NOTE PURCHASE AGREEMENT (the “Agreement”), dated as of April , 2019, by and among China SXT Pharmaceuticals, Inc., a company organized under the laws of the British Virgin Islands with offices located at 178 Taidong Rd North, Taizhou, Jiangsu, China (the “Company”) and the investor signatory hereto (the “Investor”). WHEREAS: A. Prior to the date |
|
| April 17, 2019 |
Form of Secured Promissory Notes to be issued to the Company under the Note Purchase Agreement Exhibit 4.3 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE APPLICABLE STATE SECURITIES LAWS, AND MAY NOT BE OFFERED OR SOLD IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND SUCH STATE SECURITIES LAWS, OR AN EXEMPTION FROM REGISTRATION THEREUNDER, IN EACH CASE, TO THE EXTENT APPLICABLE HERETO. SECURED PROMISSORY NOTE New Yor |
|
| April 17, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2019. Commission File Number: 001-38773 CHINA SXT PHARMACEUTICALS, INC. (Translation of registrant’s name into English) 178 Taidong Rd North, Taizhou Jiangsu, China (Address of principal |
|
| April 17, 2019 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of [], 2019, is by and among China SXT Pharmaceuticals, Inc., a company organized under the laws of the British Virgin Islands with offices located at 178 Taidong Rd North, Taizhou, Jiangsu, China (the “Company”), and the undersigned buyers (each, a “Buyer,” and collectively, the “Buyers”). R |
|
| April 17, 2019 |
China SXT Pharmaceuticals, Inc. Announces Pricing of a $15 Million PIPE Financing Exhibit 99.1 China SXT Pharmaceuticals, Inc. Announces Pricing of a $15 Million PIPE Financing TAIZHOU, China, April 17, 2019 /PRNewswire/ - China SXT Pharmaceuticals, Inc. (SXTC) (“China SXT” or the “Company”), a specialty pharmaceutical company focusing on the research, development, manufacture, marketing and sales of Traditional Chinese Medicine Pieces (“TCMPs”), today announced that it entered |
|
| April 17, 2019 |
Exhibit 10.1 EXECUTION COPY SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of April 16, 2019, is by and among China SXT Pharmaceuticals, Inc., a company organized under the laws of the British Virgin Islands with offices located at 178 Taidong Rd North, Taizhou, Jiangsu, China (the “Company”), and each of the investors listed on the Schedule of Buyers |
|
| April 17, 2019 |
Exhibit 4.1 [FORM OF [SERIES A SENIOR [SECURED] CONVERTIBLE NOTE][SERIES B SENIOR SECURED CONVERTIBLE NOTE]] NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, |
|
| April 17, 2019 |
Exhibit 10.4 MASTER NETTING AGREEMENT MASTER NETTING AGREEMENT (the “Agreement”), dated as of April , 2019, by and among China SXT Pharmaceuticals, Inc., a company organized under the laws of the British Virgin Islands with offices located at 178 Taidong Rd North, Taizhou, Jiangsu, China (the “Company”) and the investor signatory hereto (the “Investor”, and together with the Company, the “Parties” |
|
| April 17, 2019 |
Form of Warrants to be issued to the investors under the Securities Purchase Agreement Exhibit 4.2 [FORM OF SERIES [A][B] WARRANT] NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECT |
|
| March 28, 2019 |
Exhibit 99.1 China SXT Pharmaceuticals, Inc. Announces Financial Results for the Six Months Ended September 30, 2018 TAIZHOU, China, Mar. 28, 2019 /PRNewswire/ - China SXT Pharmaceuticals, Inc. (the “Company”) (NASDAQ:SXTC), a specialty pharmaceutical company focusing on the research, development, manufacture, marketing and sales of Traditional Chinese Medicine Pieces (“TCMPs”), today announced it |
|
| March 28, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2019. Commission File Number: 333-221899 CHINA SXT PHARMACEUTICALS, INC. (Translation of registrant’s name into English) 178 Taidong Rd North, Taizhou Jiangsu, China (Address of principal |
|
| March 5, 2019 |
Filed pursuant to Rule 424(b)(3) Registration Statement Number 333-221899 Prospectus Supplement Dated March 5, 2019 To the Prospectus Dated October 03, 2018, as supplemented on November 15, 2018 China SXT Pharmaceuticals, Inc. |
|
| February 15, 2019 |
SXTC / China SXT Pharmaceuticals, Inc. / Zhou Albert Feng - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 China SXT Pharmaceuticals, Inc. (Name of Company) Ordinary Shares, $0.001 Par Value Per Share (Title of Class of Securities) G2161P108 (CUSIP Number) Feng Zhou 178 Taidong Rd North, Taizhou Jiangsu, China +86-523-86298290 (Name, Address and Telephone Number of Person Autho |
|
| February 15, 2019 |
EX-7.1 2 tv513865ex7-1.htm EXHIBIT 7.1 Exhibit 7.1 Lock-Up Agreement December 31, 2018 Boustead Securities, LLC. 6 Venture, Suite 325 Irvine, CA 92618 Ladies and Gentlemen: This Lock-Up Agreement (this “Agreement”) is being delivered to Boustead Securities LLC (the “Underwriter”) in connection with the proposed Underwriting Agreement (the “Underwriting Agreement”) between China SXT Pharmaceuticals |
